MEI Pharma, Inc. announced Daniel Gold, Ph.D. will resign as Chief Executive Officer. Dr. Gold will continue to serve on the Board of Directors of the combined company. Dr. Gold's resignation is not the result of any disagreements with the Company or relating to the Company's operations, policies or practices.

David M. Urso will become Chief Executive Officer. David M. Urso has been Chief Operating Officer and General Counsel of the Company since July 2018. Prior to July 2018, Mr. Urso had been the Company's Senior Vice President of Corporate Development and General Counsel since April 2014.

Mr. Urso joined MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a privately held drug development company he co-founded in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School.

Mr. Urso received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.